ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2012
The role of CCND1 alterations during the progression of cutaneous malignant melanoma.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Pooled it
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.Cell · 2021Pooled it
- The association between CCND1 G870A polymorphism and colorectal cancer risk: A meta-analysis.Medicine · 2017Pooled it
- Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma.Nature genetics · 2015Pooled it
- The CCND1 G870A polymorphism and susceptibility to bladder cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- NSD2 and miRNAs as Key Regulators of Melanoma Response to Romidepsin and Interferon-α2b Treatment.Cancer medicine · 2025Article
- Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database.The oncologist · 2025Article
- Primary Malignant Melanoma of the Sphenoid Sinus as a Crucial Differential Diagnosis of Skull Base Tumors: A Case Report.NMC case report journal · 2025Article
- Mutation-Attention (MuAt): deep representation learning of somatic mutations for tumour typing and subtyping.Genome medicine · 2023Article
- Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas.International journal of molecular sciences · 2021Article
- Review
- Article
- Cluster correlation based method for lncRNA-disease association prediction.BMC bioinformatics · 2020Article
- Linc00467 promotes lung adenocarcinoma proliferation via sponging miR-20b-5p to activate CCND1 expression.OncoTargets and therapy · 2019Article
- Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 through the Wnt Signaling Pathway.Pathology oncology research : POR · 2019Article
- Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.Molecular cell · 2017Article
- The significant association of CCND1 genotypes with colorectal cancer in Taiwan.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Melanoma: clinical features and genomic insights.Cold Spring Harbor perspectives in medicine · 2014Review
- SPAG9 is overexpressed in human prostate cancer and promotes cancer cell proliferation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- TRIM31 is downregulated in non-small cell lung cancer and serves as a potential tumor suppressor.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well demonstrated that CCND1 amplification is a frequent event in the acral subtype of cutaneous malignant melanoma; however, its role in the other subtypes of the disease is still controversial. The objectives of this study were to evaluate genetic and expression alterations of CCND1 with a focus on primary cutaneous melanomas, to define BRAF and NRAS mutation status, and correlate the data with clinical-pathological parameters. CCND1 amplification was associated with ulceration and the localization of the metastasis. After correction for the mutation state of BRAF and NRAS genes, CCND1 amplification in samples without such mutations was associated with ulceration and sun exposure. The cyclin D1 (CCND1) mRNA level decreased in lesions with multiple metastases and was correlated with both the mRNA levels and mutation state of BRAF and NRAS genes. Primary melanomas with BRAF(V600) or NRAS(Q61 ) mutations exhibited lower CCND1 mRNA level. CCND1 protein expression was associated with Breslow thickness, metastasis formation, and shorter survival time. These observations suggest that CCND1 alterations are linked to melanoma progression and are modified by BRAF and NRAS mutations. Our data show that CCND1 amplification could have a prognostic relevance in cutaneous melanoma and highlight that altered CCND1 gene expression may influence the metastatic progression, survival, and the localization of metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.